Clinical trials: Cervix
Labor Onset and Length Abnormalities
Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
The study is designed as a randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening…
- Trial name
- NCT04000438
- Testing
- DF01, PL1
- Where
- 7 sites in Finland, Sweden
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Dilafor AB
Primary Peritoneal Carcinoma, Tumor
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological…
- Conditions
- Primary Peritoneal Carcinoma, Tumor, Epithelial Ovarian Cancer, Uterine Disease
- Trial name
- NCT00561795
- Testing
- pazopanib (GW786034), carboplatin, paclitaxel
- Where
- 5 sites in France, Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Uterine Cervical Neoplasms
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix.
- Trial name
- NCT02509585
- Testing
- Tc99m tilmanocept
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Cardinal Health 414, LLC
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Preterm Birth
Cervix Monitor for Elasticity and Length Measurements
Preterm birth is a leading global cause of neonatal mortality despite of numerous advances and intensive research in perinatal medicine.
- Trial name
- NCT03199079
- Testing
- Measurement
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Advanced Tactile Imaging, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Cervical Intraepithelial Neoplasia, Uterine Neoplasms
A Trial for Patients With Advanced/Recurrent Cervical Cancer
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00190983
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Melanoma
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ASCI])…
- Trial name
- NCT01149343
- Testing
- Immunotherapeutic GSK2302025A, different formulations
- Where
- 37 sites in Czechia, France and 4 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or…
- Trial name
- NCT00770874
- Testing
- S-1 + Cisplatin (arm A), Cisplatin (arm B)
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 375 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Preterm Birth
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34…
- Trial name
- PCP002 (NCT02225353)
- Testing
- Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, Progesterone Cervical Pessary 7.7 g
- Where
- 4 sites in Chile
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
Preterm Delivery, Short Cervix
PREGNANT Short Cervix Trial
The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.
- Conditions
- Preterm Delivery, Short Cervix, Short Uterine Cervical Length
- Trial name
- NCT00615550
- Testing
- progesterone
- Where
- 49 sites in United States, Belarus and 8 more
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Uterine Cervical Neoplasms
Irinotecan Study For Cervical Cancer
The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer
- Trial name
- NCT00136955
- Testing
- Irinotecan
- Where
- 5 sites in Taiwan
- Volunteers
- 41 people
- Sponsor
- Pfizer
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals